Biotechnology company Moderna has agreed to pay up to $2.25 billion to settle patent litigation over technology used in its COVID-19 vaccine, resolving a dispute with Arbutus Biopharma and Genevant Sciences.
The lawsuits alleged that Moderna’s vaccine relied on patented lipid nanoparticle delivery systems, a technology used to transport mRNA molecules into human cells.
Arbutus and Genevant claimed the biotechnology company incorporated elements of their patented technology without appropriate licensing.
The agreement brings an end to several legal claims tied to the intellectual property underlying Moderna’s mRNA vaccine platform.
Background to the Patent Dispute
The litigation focused on patents covering lipid nanoparticle technology, which acts as a delivery vehicle allowing fragile mRNA molecules to enter human cells. The technology is widely regarded as one of the key enabling components behind modern mRNA vaccines.
Arbutus and Genevant claimed that Moderna’s COVID-19 vaccine utilised elements of this patented delivery system without authorisation, amounting to patent infringement.
The dispute was formally brought in Arbutus Biopharma Corp. and Genevant Sciences GmbH v. Moderna Inc., filed in the U.S. District Court for the District of Delaware in 2022, after earlier legal challenges surrounding the patents used in mRNA vaccine technology.
Key Court Rulings Before Settlement
In February 2026, U.S. District Judge Joshua D. Wolson, sitting by designation in the Delaware federal court, issued several important summary-judgment rulings as the case moved toward a trial scheduled for March.
One of the most significant decisions rejected Moderna’s attempt to rely on a federal contractor immunity defence under 28 U.S.C. §1498, which can shield companies from patent infringement liability when products are manufactured “for the United States.”
The court held that the statute applied only when patented inventions were used for the benefit of the government itself, not for members of the public receiving vaccines.
As a result, the vast majority of Moderna’s government vaccine sales, reportedly worth more than $8 billion remained subject to the patent claims in the case.
The judge also ruled that Arbutus could not rely on the doctrine of equivalents to prove infringement because amendments made during the patent prosecution process created prosecution history estoppel.
Instead, the company would need to demonstrate literal infringement of the patents at trial.
Settlement Structure
Under the agreement, Moderna will make an initial payment of approximately $950 million.
The settlement also includes provisions for additional payments that could bring the total value to as much as $2.25 billion, depending on the outcome of related legal proceedings connected to the patents.
The agreement resolves existing litigation while establishing licensing arrangements tied to the disputed technology.
For Moderna, the settlement removes a major legal uncertainty surrounding the intellectual property framework underpinning its COVID-19 vaccine and broader mRNA platform.
Legal Implications for Biotechnology Companies
The case highlights the increasing importance of intellectual property rights in emerging biotechnology fields, particularly those involving platform technologies such as mRNA therapeutics.
Unlike traditional pharmaceutical patents focused on a single compound, biotechnology innovation frequently involves multiple layers of intellectual property, including delivery systems, manufacturing techniques and therapeutic applications.
This creates a complex legal landscape in which companies must navigate licensing agreements, patent portfolios and potential infringement claims while bringing new products to market.
For corporate legal teams, the dispute illustrates the importance of freedom-to-operate assessments, early licensing negotiations and robust patent strategies when developing high-value medical technologies.
Broader Impact for mRNA Patent Litigation
The settlement comes as pharmaceutical companies continue expanding the use of mRNA technology beyond COVID-19 vaccines into areas such as cancer immunotherapy and treatments for rare diseases.
As investment in mRNA platforms grows, intellectual property rights covering delivery systems, manufacturing processes and formulation techniques are becoming increasingly important for biotechnology companies.
The dispute highlights how patent protection over enabling technologies such as lipid nanoparticle delivery systems can shape competition and licensing arrangements across the rapidly developing mRNA therapeutics sector.
